| External factors: | MEK162 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Pancreatic ductal adenocarcinoma |
| Experiment: | SA-β-gal activity assay//Cell cycle analysis |
| Description: | Cell cycle analysis of BxPC-3, Panc-1, and MiaPaCa-2 cells following 48 hours of treatment with DMSO, LEE011 (1μM), MEK162 (5μM), or combination shows a reduction in S-phase fraction following combination treatment with a concomitant increase in G0/G1 fraction, suggesting cell cycle arrest at G1/S checkpoint in all cell lines. Treated cells were stained for β-galactosidase, a surrogate marker for cell senescence, and analyzed using brightfield microscopy. |
| Target gene: | ERK |
| R-EF-Target gene: | Downregulation |
| Official symbol(s): | ERK |
| Target gene experiment: | Western blot |
| Target gene description: | After treating all cell lines with escalating doses of MEK162, we observed reduced phosphorylated ERK (pERK) levels at all doses and in a time-dependent manner. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: